A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients

NCT04869228 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
380
Enrollment
INDUSTRY
Sponsor class

Stopped This decision is made on changing the development strategy of GT0918 to adapt ever-changing COVID-19 pandemic management globally.

Conditions

Interventions

Sponsor

Suzhou Kintor Pharmaceutical Inc,